Real-World check: can a new infusion drug ease advanced Parkinson's?

NCT ID NCT06965374

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 270 Italian adults with advanced Parkinson's disease who are already prescribed Foslevodopa/Foscarbidopa, a drug given as a continuous infusion under the skin. Researchers will track how the drug affects quality of life over 12 months using a standard questionnaire. The goal is to see how well the treatment works in real-world settings, outside of strict clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Foslevodopa/Foscarbidopa (a drug combination given as a continuous infusion under the skin)
What this could lead to: If successful, this study could confirm that Foslevodopa/Foscarbidopa improves daily life and symptom control for people with advanced Parkinson's in routine care.
What could go wrong: This is an observational, real-world study, not a controlled trial, so results may be less definitive. It is also limited to Italian participants, which may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 273276
RECRUITING

Turin, Piedmont, 10126, Italy
AOU San Giovanni di Dio Ruggi d'Aragona - Scuola Medica Salernitana /ID# 274319
RECRUITING

Salerno, 84131, Italy
ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO /ID# 272949
RECRUITING

Milan, Milano, 20122, Italy
AUSL di Reggio Emilia - Arcispedale Santa Maria Nuova /ID# 274388
RECRUITING

Reggio Emilia, 42122, Italy
Azienda Ospedale-Universita Padova /ID# 274317
RECRUITING

Padova, 35128, Italy
Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 273434
RECRUITING

Naples, Napoli, 80138, Italy
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone /ID# 272863
RECRUITING

Palermo, 90127, Italy
Azienda Ospedaliera Universitaria Policlinico Tor Vergata /ID# 272834
RECRUITING

Rome, Roma, 00133, Italy
Azienda Ospedaliero Universitaria Pisana /ID# 273541
RECRUITING

Pisa, 56126, Italy
Azienda Ospedaliero Universitaria delle Marche /ID# 272694
RECRUITING

Ancona, 60020, Italy
Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 273562
RECRUITING

Rome, Roma, 00161, Italy
Azienda Ulss 3 Serenissima /ID# 273027
RECRUITING

Venice, Venezia, 30100, Italy
Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 273225
RECRUITING

Milan, Milano, 20133, Italy
Fondazione Mondino Istituto Neurologico Nazionale a Carattere Scientifico IRCCS /ID# 274226
RECRUITING

Pavia, 27100, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 274539
RECRUITING

Rome, Roma, 00168, Italy
IRCCS Centro Neurolesi Bonino Pulejo /ID# 273628
RECRUITING

Messina, 98124, Italy
IRCCS Oasi SS. Troina /ID# 273507
RECRUITING

Troina, Enna, 94018, Italy
Istituto Neurologico Mediterraneo Neuromed S.P.A. - Irccs /Id# 272695
RECRUITING

Pozzilli, Isernia, 86077, Italy
Ospedale Bellaria - Azienda Usl Di Bologna /ID# 274463
RECRUITING

Bologna, 40139, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.